{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:47:01Z","timestamp":1786978021587,"version":"build-2736575974"},"reference-count":24,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2016,12,27]],"date-time":"2016-12-27T00:00:00Z","timestamp":1482796800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"},{"start":{"date-parts":[[2016,12,27]],"date-time":"2016-12-27T00:00:00Z","timestamp":1482796800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharmacology"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1002\/jcph.857","type":"journal-article","created":{"date-parts":[[2016,12,27]],"date-time":"2016-12-27T08:28:46Z","timestamp":1482827326000},"page":"777-783","source":"Crossref","is-referenced-by-count":23,"title":["Moderate Hepatic Impairment Does Not Affect Doravirine Pharmacokinetics"],"prefix":"10.1002","volume":"57","author":[{"given":"Sauzanne","family":"Khalilieh","sequence":"first","affiliation":[{"name":"Merck & Co., Inc.; Kenilworth NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka Lai","family":"Yee","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc.; Kenilworth NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Liu","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc.; Kenilworth NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Fan","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc.; Kenilworth NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa I.","family":"Sanchez","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc.; Kenilworth NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Auger","sequence":"additional","affiliation":[{"name":"Celerion; Lincoln NE USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilias","family":"Triantafyllou","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc.; Kenilworth NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Stypinski","sequence":"additional","affiliation":[{"name":"Celerion; Lincoln NE USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Lasseter","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology of Miami, Inc.; Miami FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Marbury","sequence":"additional","affiliation":[{"name":"Orlando Clinical Research Center; Orlando FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Iwamoto","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc.; Kenilworth NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,12,27]]},"reference":[{"key":"10.1002\/jcph.857-BIB0001|jcph857-cit-0001","unstructured":"World Health Organization http:\/\/www.who.int\/mediacentre\/factsheets\/fs360\/en\/"},{"issue":"9397","key":"10.1002\/jcph.857-BIB0002|jcph857-cit-0002","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/S0140-6736(03)14844-1","article-title":"Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection","volume":"362","author":"Qurishi","year":"2003","journal-title":"Lancet."},{"key":"10.1002\/jcph.857-BIB0003|jcph857-cit-0003","unstructured":"DHHS Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents 2015 http:\/\/aidsinfo.nih.gov\/guidelines"},{"issue":"4","key":"10.1002\/jcph.857-BIB0004|jcph857-cit-0004","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3851\/IMP2920","article-title":"Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects","volume":"20","author":"Anderson","year":"2015","journal-title":"Antivir Ther."},{"issue":"1","key":"10.1002\/jcph.857-BIB0005|jcph857-cit-0005","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1128\/AAC.04201-14","article-title":"In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways","volume":"59","author":"Feng","year":"2015","journal-title":"Antimicrob Agents Chemother."},{"issue":"4 suppl 3","key":"10.1002\/jcph.857-BIB0006|jcph857-cit-0006","doi-asserted-by":"crossref","first-page":"19532","DOI":"10.7448\/IAS.17.4.19532","article-title":"Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF\/FTC in ART-naive HIV-positive patients","volume":"17","author":"Gatell","year":"2014","journal-title":"J Int AIDS Soc."},{"issue":"3","key":"10.1002\/jcph.857-BIB0007|jcph857-cit-0007","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1128\/AAC.02403-13","article-title":"In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor","volume":"58","author":"Lai","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1002\/jcph.857-BIB0008|jcph857-cit-0008","unstructured":"Sanchez RI Fillgrove K Hafey M In vitro evaluation of doravirine potential for pharmacokinetic drug interactions 2015 https:\/\/issx.confex.com\/issx\/20NA\/webprogram\/Paper35163.html"},{"key":"10.1002\/jcph.857-BIB0009|jcph857-cit-0009","unstructured":"Khalilieh SG Sanchez RI Liu R Multiple-dose treatment with rifabutin reduces the exposure of doravirine. Abstract presented at CROI 2016"},{"key":"10.1002\/jcph.857-BIB0010|jcph857-cit-0010","unstructured":"Yee KL Khalilieh SG Liu R The effect of single and multiple dose rifampin on the pharmacokinetics of doravirine 2015 http:\/\/www.croiconference.org\/sites\/default\/files\/posters-2015\/521.pdf"},{"key":"10.1002\/jcph.857-BIB0011|jcph857-cit-0011","doi-asserted-by":"crossref","unstructured":"Yee KL Sanchez RI Auger P An evaluation of doravirine pharmacokinetics when switching from efavirenz to doravirine treatment 2015 http:\/\/regist2.virology-education.com\/abstractbook\/2015_4.pdf","DOI":"10.1128\/AAC.01757-16"},{"key":"10.1002\/jcph.857-BIB0012|jcph857-cit-0012","unstructured":"Fillgrove K Liang Y Lu B Metabolism of doravirine in preclinical species and humans. Abstract presented at: 20th North American International Society for the Study of Xenobiotics (ISSX) Meeting 2015"},{"issue":"8","key":"10.1002\/jcph.857-BIB0013|jcph857-cit-0013","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/bjs.1800600817","article-title":"Transection of the oesophagus for bleeding oesophageal varices","volume":"60","author":"Pugh","year":"1973","journal-title":"Br J Surg."},{"issue":"12","key":"10.1002\/jcph.857-BIB0014|jcph857-cit-0014","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00228-008-0553-z","article-title":"Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction","volume":"64","author":"Verbeeck","year":"2008","journal-title":"Eur J Clin Pharmacol."},{"issue":"4","key":"10.1002\/jcph.857-BIB0015|jcph857-cit-0015","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1086\/427216","article-title":"Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection","volume":"40","author":"Aranzabal","year":"2005","journal-title":"Clin Infect Dis."},{"issue":"6","key":"10.1002\/jcph.857-BIB0016|jcph857-cit-0016","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nrgastro.2014.17","article-title":"HCV and HIV co-infection: mechanisms and management","volume":"11","author":"Chen","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"12","key":"10.1002\/jcph.857-BIB0017|jcph857-cit-0017","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.cgh.2010.08.024","article-title":"Liver disease in the HIV-infected individual","volume":"8","author":"Price","year":"2010","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"3","key":"10.1002\/jcph.857-BIB0018|jcph857-cit-0018","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1053\/j.gastro.2009.06.040","article-title":"Coinfection with HIV-1 and HCV-a one-two punch","volume":"137","author":"Kim","year":"2009","journal-title":"Gastroenterology."},{"issue":"15","key":"10.1002\/jcph.857-BIB0019|jcph857-cit-0019","doi-asserted-by":"crossref","first-page":"7366","DOI":"10.1128\/JVI.00191-09","article-title":"Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes","volume":"83","author":"Rotman","year":"2009","journal-title":"J Virol."},{"key":"10.1002\/jcph.857-BIB0020|jcph857-cit-0020","unstructured":"European AIDS Clinical Society http:\/\/www.eacsociety.org\/Portals\/0\/Guidelines_Online_131014.pdf"},{"issue":"2","key":"10.1002\/jcph.857-BIB0021|jcph857-cit-0021","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2174\/1389200043489054","article-title":"The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes","volume":"5","author":"Elbekai","year":"2004","journal-title":"Curr Drug Metab."},{"issue":"3","key":"10.1002\/jcph.857-BIB0022|jcph857-cit-0022","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.clpt.2006.05.006","article-title":"Liver disease selectively modulates cytochrome P450-mediated metabolism","volume":"80","author":"Frye","year":"2006","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1002\/jcph.857-BIB0023|jcph857-cit-0023","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2174\/1389200043335531","article-title":"Cytochrome P450 and liver diseases","volume":"5","author":"Villeneuve","year":"2004","journal-title":"Curr Drug Metab."},{"key":"10.1002\/jcph.857-BIB0024|jcph857-cit-0024","article-title":"Efficacy and safety of doravirine 100mg QD vs efavirenz 600mg QD with TDF\/FTC in ART-naive HIV-infected patients: week 24 results","author":"Gatell","year":"2015","journal-title":"8th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.857","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.857","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/jcph.857\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T08:58:38Z","timestamp":1657789118000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jcph.857"}},"subtitle":["Khalilieh et al"],"short-title":[],"issued":{"date-parts":[[2016,12,27]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"URL":"https:\/\/doi.org\/10.1002\/jcph.857","archive":["Portico"],"relation":{},"ISSN":["0091-2700"],"issn-type":[{"value":"0091-2700","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12,27]]}}}